1. Lai, C.L.; Ching, C.K.; Tung, A.K.; Li, E.; Young, J.; Hill, A.; Wong, B.C.; Dent, J.; Wu, P.C. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis 12. B surface antigen carriers; a placebo-controlled trial. Hepatology 1997, 25, 241-244.

2. Dienstag, J.L.; Schiff, E.R.; Wright, T.L.; Perrillo, R.P.; Hann, H.W.; Goodman, Z.; Crowther, L.; Condreay, L.D.; Woessner, M.; Rubin, M.; Brown, N.A. Lamivudine as initial treatment for chronic hepatitis B in the United 13 States. N. Engl. J. Med. 1999, 341, 156-1263.

3. Liaw, Y.F.; Chien, R.N.; Yeh, C.T.; Tsai, S.L.; Chu, C.M.

Acute exacerbation and hepatitis B virus clearance after 14. emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999, 30, 567-572.

4. Markowitz, J.S.; Martin, P.; Conrad, A.J.; Markmann, J.F.; Seu, P.; Yersiz, H.; Goss, J.A.; Schmidt, P.; Pakrasi, A.; Artinian, L.; Murray, N.G.; Imagawa, D.K.; Holt, C.; Goldstein, L.I.; Stribling, R.; Busuttil, R.W. Prophylaxis 15. against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998, 28, 585-589.

5. Tassopoulos, N.C.; Volpes, R.; Pastore, G.; Heathcote, J.; 16 Buti, M.; Goldin, R.D.; Hawley, S.; Barber, J.; Condreay,

L.; Gray, D.F. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999, 29, 889896. 17.

6. Song, B.C.; Suh, D.H.; Lee, H.C.; Chung, Y.H.; Lee, Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000, 32, 803-806.

7. Lau, D.T.; Khokhar, M.F.; Doo, E.; Ghany, M.G.; Herion, D.; Park, Y.; Kleiner, D.E.; Schmid, P.; Condreay, L.D.; 18. Gauthier, J.; Kuhns, M.C.; Liang, L.J.; Hoofnagle, L.H. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000, 32, 828-834.

8. Leung, N.W.; Lai, C.L.; Chang, T.T.; Guan, R.; Lee, C.M.; 19. Ng, K.Y.; Lim, S.G.; Wu, P.C.; Dent, J.C.; Edmundson, S.; Condreay, L.D.; Chien, R.N.; on behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 20. 3 years of therapy. Hepatology 2001, 33, 1527-1532.

9. Allen, M.I.; Deslauriers, M.; Andrews, C.W.; Tipples, G.A.; Walters, K.A.; Tyrrell, D.L.; Brown, N.; Condreay, L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27, 1670-1677. 21.

10. Ling, R.; Harrison, T.J. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J. Gen. Virol. 1999, 80, 601 -606.

11. Stuyver, L.J.; Locarnini, S.A.; Lok, A.; Richman, D.D.; Carman, W.F.; Dienstag, J.L.; Schinazi, R.F.; HEP DART 22. International Committee Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33, 751 -757.

Nafa, S.; Ahmed, S.; Tavan, D.; Pichoud, C.; Berby, F.; Stuyver, L.; Johnson, M.; Merle, P.; Abidi, H.; Trepo, C.; Zoulim, F. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000, 32, 1078-1088. Kessler, H.H.; Stelzl, E.; Marth, E.; Stauber, R.E. Detection of mutations in the hepatitis B virus polymerase gene. Clin. Chem. 2003, 49, 989-992. Das, K.; Xiong, X.; Yang, H.; Westland, C.E.; Gibbs, C.S.; Sarafianos, S.G.; Arnold, E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 2001, 75, 47714779.

Melegari, M.; Scaglioni, P.P.; Wands, J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27, 628633.

Lok, A.S.; Hussain, M.; Cursano, C.; Margotti, M.; Gramenzi, A.; Grazi, G.L.; Jovine, E.; Benardi, M.; Andreone, P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000, 32, 1145-1153.

Lok, A.S.F.; Zoulim, F.; Locarnini, S.; Mangia, A.; Niro, G.; Decraemer, H.; Maertens, G.; Hulstaert, F.; De Vreese, K.; Sablon, E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivu-dine therapy: Evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 2002, 40, 3729-3734. Perillo, R.; Schiff, E.; Yoshida, E.; Statler, A.; Hirsch, K.; Wright, T.; Gutfreund, K.; Lamy, P.; Murray, A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000, 32, 129-134. Yang, H.; Westland, C.E.; Delaney, W.E.; Heathcote, E.J.; Ho, V.; Fry, J.; Brosgart, C.; Gibbs, C.S.; Miller, M.D.; Xiong, S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002, 36, 464-473.

Angus, P.; Vaughan, R.; Xiong, S.; Yang, H.; Delaney, W.; Gibbs, C.; Brosgart, C.; Colledge, D.; Edwards, R.; Ayres,

A.; Bartholomeusz, A.; Locarnini, S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenter-ology 2003, 125, 292-297.

Villeneuve, J.P.; Durantel, D.; Durantel, S.; Westland, C.; Xiong, S.; Brosgart, C.L.; Gibbs, C.S.; Parvaz, P.; Werle,

B.; Trepo, C.; Zoulim, F. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 2003, 39, 1085-1089.

Benhamou, Y.; Tubiana, R.; Thibault, V. Tenofovir disoproxil fumarate in patients with HIV and lamivu-dine-resistant hepatitis B virus. N. Engl. J. Med. 2003, 348, 177-178.

Getting Started With Dumbbells

Getting Started With Dumbbells

The use of dumbbells gives you a much more comprehensive strengthening effect because the workout engages your stabilizer muscles, in addition to the muscle you may be pin-pointing. Without all of the belts and artificial stabilizers of a machine, you also engage your core muscles, which are your body's natural stabilizers.

Get My Free Ebook

Post a comment